Table 2. Treatment details and median fecal calprotectin level.
| Treatment drug and outcome | Value | |
|---|---|---|
| Main drug for RI | ||
| Oral prednisolone | 29/45 (64.4) | |
| Anti-TNF-α | 16/45 (35.6) | |
| Main drug for maintenance therapy in patients treated with oral prednisolone for RI | ||
| 5-ASA | 8/29 (27.6) | |
| Immunomodulator | 11/29 (37.9) | |
| Anti-TNF-α | 10/29 (34.5) | |
| Optimization of anti-TNF-α during 1 year of treatment in patients with anti-TNF-α for RI | ||
| Interval shortening | 3/16 (18.8) | |
| Rate of CR after 6 months of treatment according to mediations for RI | 30/45 (66.7) | |
| Rate of ER after 1 year of treatment according to medications for RI | 24/45 (53.3) | |
| Median FC level (μg/g) | ||
| Baseline | 1,927.2 (68.1–27,903.0) | |
| After 6 weeks of treatment | 666.0 (0–2,000) | |
Values are presented as number (%) or median (range).
RI: remission induction, Anti-TNF-α: anti-tumor necrosis factor alpha, CR: clinical remission, ER: endoscopic remission, FC: fecal calprotectin.